1. 首页
  2. 产品目录

TCN 213,可逆蛋白酶体抑制剂

Bortezomib (PS-341) （订货以英文为准）

编号：B125789
CAS号：179324-69-7
分子式：C19H25BN4O4
分子量：384.24
货号 品牌 包装 目录价 您的价格 库存 数量 购买
B125789-25mg 阿拉丁 25mg ¥97.90
请登录
B125789-100mg 阿拉丁 100mg ¥205.90
请登录
B125789-5mg 阿拉丁 5mg ¥59.90
请登录
B125789-1g 阿拉丁 1g ¥1071.90
请登录
B125789-500mg 阿拉丁 500mg ¥677.90
请登录
B125789-250mg 阿拉丁 250mg ¥349.90
请登录
产品名称 Bortezomib (PS-341)
中文名称 TCN 213,可逆蛋白酶体抑制剂
CAS号 179324-69-7
分子式（M.F.） C19H25BN4O4
分子量（M.W.） 384.24
储存条件 -20°C储存
沸点684.30° C
熔点139-143°C
折光率1.56
敏感性对光线敏感
溶解性Soluble in chloroform, dimethyl sulfoxide, ethanol and methanol
存贮条件储存温度-20°C
密度1.2100
应用A selective and robust 26S proteasome inhibitor
产品介绍Bortezomib (硼替佐米; PS-341) 是20S蛋白酶体抑制剂，Ki为0.6 nM。
备注Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM.
生化机理Bortezomib, a first-in-class proteasome inhibitor, induces apoptosis and growth arrest and reverses chemoresistance in myeloma cells and has demonstrated no irreversible adverse effect on haematopoietic stem cells. Bortezomib has shown in vitro and in vivo activity against a variety of malignancies, including myeloma, chronic lymphocytic leukemia, prostate cancer, pancreatic cancer, and colon cancer. The drug is rapidly cleared from the vascular compartment. Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cell lymphomas.
别名保特佐米; 硼替佐米; ((1R)-3-甲基-1-(((2S)-1-氧-3-苯基-2-((吡嗪甲酰)氨基)丙基)氨基)丁基)-硼酸;;PS-341;PS341;PS 341; Velcade;Radiciol;((1r)-3-methyl-1-(((2s)-1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-boronic acid; (R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid, BTZ, LDP-341, LDP341, MG341, MLN-341, MLN341, Proteasome Inhibitor XXII, MG-341, Pyz-Phe-boroLeu
搜索质检报告(COA)
搜索MSDS
相关产品